U.S. Markets close in 3 hrs 17 mins


. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press49 minutes ago

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    The Food and Drug Administration has approved the first inhaler that combines three medicines to ease breathing in patients with emphysema or chronic bronchitis.

  • 3 Stocks to Buy with Dividend Yields Above 3%
    Motley Fool5 hours ago

    3 Stocks to Buy with Dividend Yields Above 3%

    Good things come in threes. Here are three solid stocks in three different industries with greater than 3% yields.

  • Reuters9 hours ago

    GlaxoSmithKline breathes easier as U.S. approves triple lung drug

    U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting Britain's biggest drugmaker ahead of rivals such as AstraZeneca and Novartis.